¤³¤Î¥Ú¡¼¥¸¡ÊÕÜÌ¾é» vs ¸¶¾³é»¡§POXET-60 °Ù½ºÖ÷¹¹¼õÃËÀ­ÀÄ睞¡©¡ËÆâ¤Î¥¹¥­¥Ã¥×¥á¥Ë¥å¡¼
  1. ¥µ¥¤¥È¤Î¥á¥¤¥ó¥á¥Ë¥å¡¼¤Ø°Üư
  2. ¥µ¥¤¥È¤Î¥æ¡¼¥¶¥á¥Ë¥å¡¼¤Ø°Üư
  3. ¤³¤Î¥Ú¡¼¥¸¡ÊÕÜÌ¾é» vs ¸¶¾³é»¡§POXET-60 °Ù½ºÖ÷¹¹¼õÃËÀ­ÀÄ睞¡©¡Ë¤Î¥á¥¤¥ó¥³¥ó¥Æ¥ó¥Ä¤Ø°Üư

°Ê²¼¡¢¤³¤Î¥Ú¡¼¥¸(ÕÜÌ¾é» vs ¸¶¾³é»¡§POXET-60 °Ù½ºÖ÷¹¹¼õÃËÀ­ÀÄ睞¡©)¤Î¥á¥¤¥ó¥³¥ó¥Æ¥ó¥Ä¤Ç¤¹¡£

¥³¥ß¥å¥Ë¥Æ¥£¡§
ÕÜÌ¾é» vs ¸¶¾³é»¡§POXET-60 °Ù½ºÖ÷¹¹¼õÃËÀ­ÀÄ睞¡©¡Ê¤´¶á½ê¤Î³¹¥Í¥¿¡Ë

ÕÜÌ¾é» vs ¸¶¾³é»¡§POXET-60 °Ù½ºÖ÷¹¹¼õÃËÀ­ÀÄ睞¡©
¥²¥¹¥È ºßÂæßÔ¡¤ÃËÀ­ÊÝ·ò»Ô¾ìÆü±×À®½Ï¡¤±ÛÐÔ±Û¿ÃËÀ­³«»ÏÀµ»ë¡ÖÁá±Ì¡×Çç¸ÄµÄÂê¡£»ÔÌ̾å½üλÃÎ̾Ū¸¶¾³é» É¬ÍøÒ¦¡ÊPriligy¡Ë ³°¡¤Ìé½Ð¸½Î»µö¿ÉʼÁÍ¥ÎÉŪÕÜ̾黡¤Â¶ÃæºÇ¼õÝÄ·ÞŪÇü²á±÷ POXET-60 É¬ÍøÒ¦ÕÜ̾黡£

ÆáÖ÷¡¤°Ù½ºÖ÷±ÛÐÔ±Û¿ÃËÀ­ÐòÁªÚ¤ POXET-60 ¼©ÉÔÀ§¸¶¾³É¬ÍøÒ¦¡©ËÜʸÕò×ÏÀ®Ê¬¡¢Úò̡¢Ñ«³Ê¡¢°ÂÁ´À­çÐÎ×¾²ÚËÚ¡¸ÞÂçÌ̸þ¿¼ÆþʬÀÏ¡¤Öè你λ²ò POXET-60 Í­ÚÃ嗎¡¢POXET-60 °ÂÁ´嗎¡¢POXET-60 ×ãÖ÷µÉ Åù¾ï¸«µ¿Ìä¡£

​1220..0.png

°ì¡¢À®Ê¬ÁêÆ±¡¤Î×¾²ëúÕéÚò̰ìÃ×
POXET-60 ŪÀ®Ê¬°Ù ãÇñÀ¾Äõ¡ÊDapoxetine¡Ë60mg¡¤Çççи¶¾³ É¬ÍøÒ¦¡ÊPriligy¡Ë À®Ê¬´°Á´ÁêÆ±¡£Ã£ÇñÀ¾ÄõÖ¤±÷ ÁªÚ¤À­·ìÀ¶ÁǺƵÛÚÀÍÞÀ©Ñý¡ÊSSRI¡Ë¡¤Ç½Í­Úñä´Ë¼ÍÀºÈ¿¼Í»þ´Ö¡¢±äĹÀ­À¸³è»ýåô»þ´Ö¡£

º¬Ú¡¡ÔThe Journal of Sexual Medicine¡Õ2006 ǯâ¤É½Åª°ì¹à¡ÒÖÌÕÎ×¾²¸¦µæ¡ÊKaufman et al., 2006¡Ë¡¤

ÉþÍÑãÇñÀ¾Äõ 60mg ŪÃËÀ­¡¤Â¶Ê¿¶Ñ¼ÍÀºßªÉú»þ´Öͳ 0.9 ʬ¾â±äĹ»ê 3.5 ʬ¾â¡¤Þà°ÕÅÙðýÃøÄ󾣡£

º¡³°¡¤¡ÔUrology¡Õ´ü´© 2008 ǯ¸¦µæ»Ø½Ð¡¤Ã£ÇñÀ¾ÄõÕô±÷ Áá±Ì²þÁ±Î¨Ã£ 77%¡¤³îºßÄä黸åлǽ°Ý»ý°ìÄê¿´ÍýãÓÄêÀ­¡£

ÇçëúÌÀ POXET-60 ±ä»þÚÃ²Ì çи¶¾³É¬ÍøÒ¦ÅùƱ¡¤é»ÍýºîÍÑ´°Á´°ìÃס¤Ç½幫½õÃËÀ­Í­ÚñäĹ»þ´Ö¡¢²þÁ±¹µÀ©ÎÏ¡£



Æó¡¢Ñ«³Ê¹¹¿ÆÌ±¡¤Ä¹´üÉþÍÑÉéÙ¿Äã
Õôµö¿ÃËÀ­ÐÔ說¡¤POXET-60 Ñ«³Ê À§·èÄê¹ØÇãŪï𸰰øÁÇ¡£
ͳ±÷ÕÜ̾é»ÉÔ¼û½Å¿·¸¦â¤¡¤ÂþÍ×ÇÛÊý¡¢ÑýÎÌçÐé»ÚÃãɸ¨²Ä¾å»Ô¡¤°øº¡À®ËÜÂçÉý¹ßÄã¡£º¬Ú¡¡ÔEuropean Journal of Health Economics¡Õ¸¦µæðý¼¨¡¤ÕÜ̾黾å»Ô¸å²ÄìªÆ±Îàé»ÊªÑ«³ÊÊ¿¶Ñ²¼¹ß 40%¡Á80%¡£

°ÊÂæßÔ»Ô¾ì¹Ô¾ð·×»»¡¤°ìâ¶ POXET-60¡Ê4 ðùêæ¡Ë ÅªÑ«³Ê¶ÏÌ󸶾³ É¬ÍøÒ¦ Ū»°Ê¬Ç·°ì¡£
Õô±÷Ĺ´üÉþÍÑ¡¢°¿ÁÛ¾¨»î²þÁ±Áá±ÌŪÃËÀ­¼©¸À¡¤ÇçÜëŪ¹â À­Ñ«Èæ ̵µ¿¹¹¶ñµÛ°úÎÏ¡£
ÉÔ¾¯»ÈÍѼԺßÏÀÃÅɽ¼¨¡§¡ÖPOXET-60 çÐÉ¬ÍøÒ¦º¹ÊÌÂþºßÑ«³Ê¡¤Úò̴ö¸ÃÁêÆ±¡£¡×

152323.png

»°¡¢Ä̲áÔ¢ºÝÀ½é»Ç§ëú¡¤POXET-60 °ÂÁ´嗎¡©
°ÂÁ´À­°ìľÀ§ÃËÀ­ºÇïð¿´ÅªµÄÂê¡£POXET-60 ͳ°õÅÙÃÎ̾黾³ Sunrise Remedies Pvt. Ltd. À½Â¤¡¤³º¸ø»ÊÄ̲á WHO-GMP¡ÊÀ¤³¦±ÒÀ¸ÁÈ¿¥Îɹ¥À½Â¤µ¬ÈÏ¡Ë çÐ ISO 9001 ÉʼÁǧëú¡£
Çç°ÕÌ£Ãøé»Éʺ߸¶ÎÁ¡¢ÑýÎÌ¡¢À½ÄøçÐÊñêæ¾å¡¤¶ÑÉä¹çÔ¢ºÝîÐé»À¸產ɸ½à¡£

º¬Ú¡¡ÔInternational Journal of Basic & Clinical Pharmacology¡Õ2020 ǯŪ¸¦µæ»Ø½Ð¡¤

å´ WHO-GMP ǧëúŪ°õÅÙÕÜ̾黺ßé»ÍýµÛÚÀΨ¡ÊBioavailability¡Ëçи¶¾³é»´ö¸Ã̵º¹¡¤º¹µ÷¶Ï 3% °Ê內¡¤Ö¤Î×¾²ÅùÚÃÈÏÔ£¡£

ÇçÌéÂåɽ¡¤å´Àµµ¬´ÉÆ»¹ØÇãŪ POXET-60 É¬ÍøÒ¦ÕÜÌ¾é» ºß°ÂÁ´À­çÐãÓÄêÀ­¾å´°Á´²Ä°Ê¿®ûò¡£

¼ãÁÛÈòÌȹØÇãÅþÐñ黡¤·úµÄÙÓ¿Ò¡ÖPOXET-60 哪ΣÇã¡×»þÁªÚ¤¶ñ´±Êý¼øÜÞ°¿é»»Õ»ðëÎÅªÊ¿Âæ

»Í¡¢POXET-60 »ÈÍÑ¿´ÆÀ¡§µ¯ÚÃãÓÄê¡¢ÉûºîÍÑíËÈù
º¬Ú¡»ÈÍѼÔçÐÎ×¾²ë·»¡»ñÎÁ¡¤POXET-60 µ¯Úûþ´ÖÌó°Ù 1 ¾®»þº¸±¦¡£
¶¼çÍ×ÉûºîÍѰÙíËÈùƬÚô¡¢¸ý´¥°¿»Ã»þÀ­·ñÂÕ¡¤Ã¢â¤À¸Î¨Äã±÷ 10%¡£
º¬Ú¡¡ÔClinical Pharmacology & Therapeutics¡Õ´ü´©Êó¹ð¡¤

ãÇñÀ¾ÄõŪÉûºîÍÑ¿°Ùû»Ã³î²ÄµÕÀ­¡¤ÉÔÐò¤À®À®癮°¿¿´Íý°Íûò¡£

ºß³ÆÂçÏÀÃÅŪ POXET-60 »ÈÍÑ¿´ÆÀʬµý Ãæ¡¤ÉÔ¾¯ÃËÀ­É½¼¨¡§

À­¹Ô°Ù»ýµ×»þ´Ö±äĹ 2¡Á3 ÇÜ

¾Çθ´¶ÌÀðý¹ßÄ㡤²áÄø¹¹¼«Á³

Ää黸å̵²üÚÒÈ¿Øæ¡¤¿Èñó狀ÂÖãÓÄê

°øº¡¡¤µöÂ¿ÂæßÔÃËÀ­Õò POXET-60 ±ä»þ黿äÁ¦ µëÊþͧºî°ÙÀ­¸ùǽ²þÁ±Åª¼óÁªÊý°Æ¡£

213232.0.png

¸Þ¡¢POXET-60 ŬÍѲ·²çÐÀµ³ÎÉþÍÑÊý¼°
POXET-60 ŬÍѲ·²Êñ³ç¡§

íËÅÙÅþÃæÅÙÁá±Ì´µ¼Ô

ÁÛ±äĹÀ­°¦»þ´Ö¡¢²þÁ±¹µÀ©ÎϼÔ

Õô¸¶¾³É¬ÍøÒ¦Ñ«³ÊÍ­ÉéÙ¿¼Ô

¶ö¼¤¼ûÍ×Êå½õ±ä»þŪ¿·º§°¿ÔÚÎϲ·²

POXET-60 ×ãÖ÷µÉ¡©
·úµÄ±÷À­¹Ô°ÙÁ° 1¡Á3 ¾®»þÉþÍѰìðù¡Ê60mg¡Ë¡¤°ÊÀ¶¿å吞Éþ¡£ÈòÌȰû¼òçÐÌýç·¿©Êª¡¤°ÊÌȱƶÁµÛÚÀ¡£

¼ã¼ó¼¡ÉþÍÑ¡¤·úµÄ»ðëÎîлÕÉ¾ÐÆÑýÎÌçÐÅ¬ØæÀ­¡£

320320.jpg

Ï»¡¢·ë¸ì¡§ÜÞ°ÒÚËÚ¡»Ù»ý¡¤POXET-60 À§ÕéØªËô²ÄðÑŪÁªÚ¤
Áî¹çÎ×¾²¸¦µæçлÈÍѼÔå´ñäÐÔ´Ç¡¤POXET-60 É¬ÍøÒ¦ÕÜÌ¾é» °Ê¶ãÓÄêé»ÚᢹçÍýÑ«³Êçйâ°ÂÁ´À­¡¤À®°Ùµö¿ÃËÀ­Åª¼óÁª¡£

ºß¡ÖÕÜÌ¾é» vs ¸¶¾³é»¡×ÅªÈæ³ÓÃæ¡¤POXET-60 ÚòÌÅùƱ¡¤¹¹Ç½¹ßÄãĹ´üå´ß»ÉéÙ¿¡£
ÅëÇÛ·ò¹¯À¸³èçп´ÍýÄ´À°¡¤POXET-60 ǽ幫½õÃËÀ­½Å½¦¼«¿®¡¢²þÁ±ÑÀÀ­ï𷸡¤Êµý¼õ¹¹»ýµ×Ū¹¬Ê¡ñóñä¡£

Áêïð產ÉÊ¿äÁ¦¡§°õÅÙÒÖÚÃÜÛ°ÒÔã °õÅÙ¿ÀÌý±ä»þÊ®Ñý¶âºÈÇ ÀµÉʹá¹ÁÏ·ÃæîÐ ²ÃÙ½Âç¿Ê¸ýVIMAXùáÂç´Ý ½÷ÍÑÈþÔ¢key ùþÔ¢üî螞µÂ ͵éÒÖÚÃÜÛ°ÒÔãLevifil ¹¹Â¿產Éʾܾð¿ÊÆþ¹¯ÜÛé»¶É¡§www.kl19.tw24¾®»þµÒÉþline:kl198888 »ðëÎ

±ä¿­閱즡§POXET-60 Ŭ¹çï¡©×ÏíËÅÙÅþÓî½ÅÁá±ÌŪ¼£ÎÅ·úµÄ
 

¤³¤Î¥¹¥ì¥Ã¥É¡ÊÕÜÌ¾é» vs ¸¶¾³é»¡§POXET-60 °Ù½ºÖ÷¹¹¼õÃËÀ­ÀÄ睞¡©¡Ë¤ËÅê¹Æ

[Åê¹Æµ­»ö¤Îºï½ü¥¬¥¤¥É¥é¥¤¥ó¤Ï¤³¤Á¤é¡ÊPDF¡Ë]

Âê̾
¥²¥¹¥È̾
Åê¹ÆËÜʸ
²èÁü¤ÎÅê¹Æ


°Ê²¼¡¢¤³¤Î¥µ¥¤¥È(¤ß¤ó¤Ê¤ÎÁ¥¶¶)¤Î¥æ¡¼¥¶ÍÑ¥á¥Ë¥å¡¼¤È¡¢ÅÐÏ¿¤µ¤ì¤¿Á¥¶¶ Çð »ÔÀî ½¬»ÖÌî ȬÀéÂå ¤Î´ë¶È¤ªÅ¹¾ðÊó¤Î¥«¥Æ¥´¥ê°ìÍ÷¤Ç¤¹¡£
¤³¤Î¥Ú¡¼¥¸¤ÎÀèÆ¬¤ØÌá¤ë

¤ª¤Ï¤è¤¦¤´¤¶¤¤¤Þ¤¹
¥²¥¹¥È¤µ¤ó

¥²¥¹¥È¤µ¤ó